Glucotrack, Inc. priced its public offering on Wednesday, setting the common stock price at $2.04 per share for 169,388 shares. The offering also included pre‑funded warrants allowing the purchase of up to 1,350,220 shares at an exercise price of $2.039 per warrant. Dawson James Securities, Inc. acted as the sole placement agent. Gross proceeds are expected to be about $3.1 million, with the closing anticipated on or about Friday, subject to customary conditions.
The proceeds will support the development of Glucotrack Technologies, Inc.’s long‑term implantable continuous blood glucose monitoring system for people with diabetes, a project pursued through its subsidiary LŌkahi Therapeutics. The offering was registered under a Form S‑3 filed with the Securities and Exchange Commission, which became effective on October 3, 2024.
